Serum vascular endothelial growth factor in the course of transcatheter arterial embolization of Hepatocellular Carcinoma

Hidekazu Suzuki, Mikiji Mori, Chizuko Kawaguchi, Masayuki Adachi, Soichiro Miura, Hiromasa Ishii

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

We previously reported that in vitro hypoxic condition enhanced VEGF level and its receptor expression in hepatic cancer cell line, HepG2. Transcatheter hepatic arterial embolization (TAE) therapy is one of the vasculoocclusive and hypoxic challenges to hepatocellular carcinoma (HCC). Therefore, we examined the level of VEGF in sera of patients with HCC who underwent TAE during the course of the treatment. Thirty-eight patients with HCC and hepatitis C virus-positive cirrhosis were studied. Peripheral blood samples were taken before and 1, 3 and 7 days after TAE with informed consent. The serum levels of VEGF as well as hepatocyte growth factor (HGF), another hepatic remodeling factor, were measured. The molar ratio (BTR) of serum branched chain amino acid (BCAA) to tyrosine (Tyr), the serum levels of AST, ALT and LDH were also examined. Although the level of AST, ALT and LDH reached the peak value within 1 day after TAE, VEGF level increased significantly 7 days later. On the other hand, there were no significant alterations in the levels of HGF and BTR during the course of TAE. Although the level of HGF was significantly correlated with the level of VEGF before TAE, this correlation was no more observed after TAE. These data collectively suggest that VEGF may be secreted in response to clinical hypoxic intervention, TAE, independent of HGF or altered amino acid metabolism. VEGF may play a role as a sensitive marker for tumor ischemia.

Original languageEnglish
Pages (from-to)1087-1090
Number of pages4
JournalInternational Journal of Oncology
Volume14
Issue number6
Publication statusPublished - 1999 Jun

Fingerprint

Vascular Endothelial Growth Factor A
Hepatocellular Carcinoma
Liver
Hepatocyte Growth Factor
Serum
Branched Chain Amino Acids
Liver Neoplasms
Tumor Biomarkers
Informed Consent
Hepacivirus
Tyrosine
Hepatocytes
Fibrosis
Ischemia
Amino Acids
Cell Line
Therapeutics

Keywords

  • Angiogenesis
  • Branched chain amino acid
  • Hepatocyte growth factor
  • Tyrosine

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Serum vascular endothelial growth factor in the course of transcatheter arterial embolization of Hepatocellular Carcinoma. / Suzuki, Hidekazu; Mori, Mikiji; Kawaguchi, Chizuko; Adachi, Masayuki; Miura, Soichiro; Ishii, Hiromasa.

In: International Journal of Oncology, Vol. 14, No. 6, 06.1999, p. 1087-1090.

Research output: Contribution to journalArticle

Suzuki, H, Mori, M, Kawaguchi, C, Adachi, M, Miura, S & Ishii, H 1999, 'Serum vascular endothelial growth factor in the course of transcatheter arterial embolization of Hepatocellular Carcinoma', International Journal of Oncology, vol. 14, no. 6, pp. 1087-1090.
Suzuki, Hidekazu ; Mori, Mikiji ; Kawaguchi, Chizuko ; Adachi, Masayuki ; Miura, Soichiro ; Ishii, Hiromasa. / Serum vascular endothelial growth factor in the course of transcatheter arterial embolization of Hepatocellular Carcinoma. In: International Journal of Oncology. 1999 ; Vol. 14, No. 6. pp. 1087-1090.
@article{b64df57b63f74ca88654219a7da66e9f,
title = "Serum vascular endothelial growth factor in the course of transcatheter arterial embolization of Hepatocellular Carcinoma",
abstract = "We previously reported that in vitro hypoxic condition enhanced VEGF level and its receptor expression in hepatic cancer cell line, HepG2. Transcatheter hepatic arterial embolization (TAE) therapy is one of the vasculoocclusive and hypoxic challenges to hepatocellular carcinoma (HCC). Therefore, we examined the level of VEGF in sera of patients with HCC who underwent TAE during the course of the treatment. Thirty-eight patients with HCC and hepatitis C virus-positive cirrhosis were studied. Peripheral blood samples were taken before and 1, 3 and 7 days after TAE with informed consent. The serum levels of VEGF as well as hepatocyte growth factor (HGF), another hepatic remodeling factor, were measured. The molar ratio (BTR) of serum branched chain amino acid (BCAA) to tyrosine (Tyr), the serum levels of AST, ALT and LDH were also examined. Although the level of AST, ALT and LDH reached the peak value within 1 day after TAE, VEGF level increased significantly 7 days later. On the other hand, there were no significant alterations in the levels of HGF and BTR during the course of TAE. Although the level of HGF was significantly correlated with the level of VEGF before TAE, this correlation was no more observed after TAE. These data collectively suggest that VEGF may be secreted in response to clinical hypoxic intervention, TAE, independent of HGF or altered amino acid metabolism. VEGF may play a role as a sensitive marker for tumor ischemia.",
keywords = "Angiogenesis, Branched chain amino acid, Hepatocyte growth factor, Tyrosine",
author = "Hidekazu Suzuki and Mikiji Mori and Chizuko Kawaguchi and Masayuki Adachi and Soichiro Miura and Hiromasa Ishii",
year = "1999",
month = "6",
language = "English",
volume = "14",
pages = "1087--1090",
journal = "International Journal of Oncology",
issn = "1019-6439",
publisher = "Spandidos Publications",
number = "6",

}

TY - JOUR

T1 - Serum vascular endothelial growth factor in the course of transcatheter arterial embolization of Hepatocellular Carcinoma

AU - Suzuki, Hidekazu

AU - Mori, Mikiji

AU - Kawaguchi, Chizuko

AU - Adachi, Masayuki

AU - Miura, Soichiro

AU - Ishii, Hiromasa

PY - 1999/6

Y1 - 1999/6

N2 - We previously reported that in vitro hypoxic condition enhanced VEGF level and its receptor expression in hepatic cancer cell line, HepG2. Transcatheter hepatic arterial embolization (TAE) therapy is one of the vasculoocclusive and hypoxic challenges to hepatocellular carcinoma (HCC). Therefore, we examined the level of VEGF in sera of patients with HCC who underwent TAE during the course of the treatment. Thirty-eight patients with HCC and hepatitis C virus-positive cirrhosis were studied. Peripheral blood samples were taken before and 1, 3 and 7 days after TAE with informed consent. The serum levels of VEGF as well as hepatocyte growth factor (HGF), another hepatic remodeling factor, were measured. The molar ratio (BTR) of serum branched chain amino acid (BCAA) to tyrosine (Tyr), the serum levels of AST, ALT and LDH were also examined. Although the level of AST, ALT and LDH reached the peak value within 1 day after TAE, VEGF level increased significantly 7 days later. On the other hand, there were no significant alterations in the levels of HGF and BTR during the course of TAE. Although the level of HGF was significantly correlated with the level of VEGF before TAE, this correlation was no more observed after TAE. These data collectively suggest that VEGF may be secreted in response to clinical hypoxic intervention, TAE, independent of HGF or altered amino acid metabolism. VEGF may play a role as a sensitive marker for tumor ischemia.

AB - We previously reported that in vitro hypoxic condition enhanced VEGF level and its receptor expression in hepatic cancer cell line, HepG2. Transcatheter hepatic arterial embolization (TAE) therapy is one of the vasculoocclusive and hypoxic challenges to hepatocellular carcinoma (HCC). Therefore, we examined the level of VEGF in sera of patients with HCC who underwent TAE during the course of the treatment. Thirty-eight patients with HCC and hepatitis C virus-positive cirrhosis were studied. Peripheral blood samples were taken before and 1, 3 and 7 days after TAE with informed consent. The serum levels of VEGF as well as hepatocyte growth factor (HGF), another hepatic remodeling factor, were measured. The molar ratio (BTR) of serum branched chain amino acid (BCAA) to tyrosine (Tyr), the serum levels of AST, ALT and LDH were also examined. Although the level of AST, ALT and LDH reached the peak value within 1 day after TAE, VEGF level increased significantly 7 days later. On the other hand, there were no significant alterations in the levels of HGF and BTR during the course of TAE. Although the level of HGF was significantly correlated with the level of VEGF before TAE, this correlation was no more observed after TAE. These data collectively suggest that VEGF may be secreted in response to clinical hypoxic intervention, TAE, independent of HGF or altered amino acid metabolism. VEGF may play a role as a sensitive marker for tumor ischemia.

KW - Angiogenesis

KW - Branched chain amino acid

KW - Hepatocyte growth factor

KW - Tyrosine

UR - http://www.scopus.com/inward/record.url?scp=0033141411&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033141411&partnerID=8YFLogxK

M3 - Article

C2 - 10339662

AN - SCOPUS:0033141411

VL - 14

SP - 1087

EP - 1090

JO - International Journal of Oncology

JF - International Journal of Oncology

SN - 1019-6439

IS - 6

ER -